вЂњWe are committed to developing innovative new medicines to their fullest potential,вЂќ said Elliott Sigal, M.D., Ph.D., Executive Vice President, Chief Scientific Officer and President, Research and Development, Bristol-Myers Squibb. вЂњThe approval of this new indication for ABILIFY provides clinicians with expanded treatment options that can help address the therapeutic needs of this population.вЂќ вЂњWe are pleased that the FDA has approved ABILIFY to treat pediatric patients aged 10 to 17 years suffering from Bipolar I Disorder,вЂќ said Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer, Otsuka Pharmaceutical Development and Commercialization, Inc. The approval is based on results from a four-week, multicenter, randomized, double-blind, placebo-controlled study in pediatric patients (10 to 17 years old) with Bipolar I Disorder that demonstrated efficacy with ABILIFY compared to placebo on the primary efficacy endpoint, mean change from baseline to Week 4 on the Young-Mania Rating Scale (Y-MRS) Total Score. вЂњThe availability of an additional treatment option that can help guide decisions in managing Bipolar I Disorder in children and adolescents is welcome news.вЂќ вЂњPediatric bipolar illness is a serious condition,вЂќ said Christoph Correll, M.D., Medical Director, Recognition and Prevention Program, The Zucker Hillside Hospital and Assistant Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Glen Oaks, New York. ABILIFY has been approved for the acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adults since September 2004 and March 2005, respectively. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFYВ® (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old). and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. TOKYO & PRINCETON, N.J.-(BUSINESS WIRE)-Otsuka Pharmaceutical Co., Ltd.

Otsuka-Sponsored Study Evaluated Use of ABILIFY in This Patient Population

Abilify medication